Physician
Gastroenterology
Dr. James F. Trotter, MD
|
|
Give Review
James F. Trotter works in the field of Gastroenterology. He attended Emory University School of Medicine. Emory University School of Medicine is ranked 23/42 in Research/PrimaryCare. He received awards:"Regional Top Doctor". James Trotter is a published physician. He has 99 publications published. The most current publication "Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis." James Trotter accepts Medicare payments and is registered with Medicare.gov.
Publications
- Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C Cirrhosis.
- Telaprevir- and Boceprevir-Based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study.
- Everolimus in liver transplantation.
- Hepatitis C Genotype Influences Post-Liver Transplant Outcomes.
- Challenges in Living Donor Liver Transplantation.
- A US Multicenter Study of Hepatitis C Treatment of Liver Transplant Recipients with Protease-Inhibitor Triple Therapy.
- The Impact of Left Ventricular Hypertrophy on Survival in Candidates for Liver Transplantation.
- Impact of the Hepatopulmonary Syndrome MELD Exception Policy on Outcomes of Patients After Liver Transplantation: An Analysis of the UNOS Database.
- Risk of Hernia Incarceration following Transjugular Intrahepatic PortoSystemic Shunt Placement.
- Multicenter review of liver transplant for hepatitis B-related liver Disease: disparities in gender and ethnicity.
- Computerized assessment of competence-related abilities in living liver donors: the Adult-to-Adult Living Donor Liver Transplantation Cohort Study.
- Sirolimus and cardiovascular Disease risk in liver transplantation.
- Differential effects of donor and recipient IL28B and DDX58 SNPs on severity of HCV after liver transplantation.
- Acute liver failure due to disseminated herpes simplex virus following thymectomy.
- Intensive care unit management of liver-related coagulation Disorders.
- Renal dysfunction and the liver transplant recipient; novel strategies for determination of reversibility and renal protective therapies pretransplant and posttransplant.
- Immunosuppression and hepatocellular carcinoma.
- Hot topic debate on HCV: The type of immunosuppression matters.
- Sirolimus--it doesn''t deserve its bad Rap(a).
- Effect of tacrolimus on survival in Hepatitis C-infected patients after liver transplantation.
- Long-Term Follow-Up of Liver Transplantation for Budd-Chiari Syndrome With Antithrombotic Therapy Based on the Etiology.
- Is MELD Fit Enough?
- Metastatic breast cancer presenting as acute liver failure.
- Operational tolerance after liver transplantation: raising the bar or tripping up?
- HBIg discontinuation with maintenance oral anti-viral therapy and HBV vaccination in liver transplant recipients.
- Health-related quality of life and survival in liver transplant candidates.
- Spontaneous clearance of Hepatitis C virus after liver transplantation.
- Practical management of acute liver failure in the Intensive Care Unit.
- International normalized ratio of prothrombin time in the model for end-stage liver Disease score: an unreliable measure.
- Liver transplantation for autoimmune Hepatitis and the success of aggressive corticosteroid withdrawal.
- Sirolimus conversion for renal preservation in liver transplantation: not so fast.
- Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.
- Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course.
- Hepatocellular carcinoma in a noncirrhotic patient with hereditary hemochromatosis.
- Expanding donor options: marginal, living, and split donors.
- Arterioportal fistula requiring liver transplantation.
- Documented deaths of hepatic lobe donors for living donor liver transplantation.
- Single-center experience of 39 patients with preoperative portal vein thrombosis among 404 adult living donor liver transplantations.
- Coagulation abnormalities in patients who have liver Disease.
- Enterobacter cancerogenus bacteremia in a patient with poor dentition, Cirrhosis, and a variceal bleed.
- Endoscopic gallbladder stent placement for treatment of symptomatic cholelithiasis in patients with end-stage liver Disease.
- Development of the allocation System for deceased donor liver transplantation.
- Torulopsis glabrata fungemia from infected transjugular intrahepatic portoSystemic shunt stent.
- Specific laboratory methodologies achieve higher model for endstage liver Disease (MELD) scores for patients listed for liver transplantation.
- MELD scores of liver transplant recipients according to size of waiting list: impact of organ allocation and patient outcomes.
- Living donor liver transplantation and Hepatitis C.
- Impact of pretransplant diagnosis of hepatocellular carcinoma on cadveric liver allocation in the era of MELD.
- The effects of desflurane and propofol on portoSystemic pressure in patients with portal hypertension.
- Hepatitis C virus therapy, hepatocyte drug Metabolism, and risk for acute cellular rejection.
- Living donor liver transplantation in patients with Hepatitis C.
- Transmission of Hepatitis C by implantation of a processed bone graft. A case report.
- Hepatocellular carcinoma extension into the right atrium.
- Selection of donors for living donor liver transplantation.
- Model for End-Stage Liver Disease score does not predict patient or graft survival in living donor liver transplant recipients.
- Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation.
- Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications.
- Comprehensive cost comparison of adult-adult right hepatic lobe living-donor liver transplantation with cadaveric transplantation.
- Adult-to-adult Right Hepatic Lobe Living Donor Liver Transplantation.
- Erythrocytosis in a patient with hepatocellular carcinoma.
- A survey of current liver biopsy practice patterns.
- Adult-to-adult transplantation of the right hepatic lobe from a living donor.
- Living donor liver transplant recipients achieve relatively higher immunosuppressant blood levels than cadaveric recipients.
- Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men.
- Laboratory test results after living liver donation in the adult-to-adult living donor liver transplantation cohort study.
- Hospitalization rates before and after adult-to-adult living donor or deceased donor liver transplantation.
- Genetic risk factors for hepatopulmonary Syndrome in patients with advanced liver disease.
- Renal function and MELD: being direct is better.
- Hemostasis and thrombosis in patients with liver Disease: the ups and downs.
- Corticosteroid elimination in simultaneous liver-kidney transplantation recipients.
- Requiem for a champion? Living donor liver transplantation.
- Vapreotide: a somatostatin analog for the treatment of acute variceal Bleeding.
- Multicentric outcome analysis of sirolimus-based immunosuppression in 252 liver transplant recipients.
- Plasma levels of S100A4 in portopulmonary hypertension.
- Genetic risk factors for portopulmonary hypertension in patients with advanced liver Disease.
- Preoperative transjugular intrahepatic portosystemic shunt (TIPS) for cirrhotic patients undergoing Abdominal and pelvic surgeries.
- Outcomes of living donor liver transplantation for acute liver failure: the adult-to-adult living donor liver transplantation cohort study.
- Donor morbidity after living donation for liver transplantation.
- Clinical risk factors for portopulmonary hypertension.
- Impact of hepatopulmonary Syndrome on quality of life and survival in liver transplant candidates.
- Improvement in survival associated with adult-to-adult living donor liver transplantation.
- Is LDLT appropriate for patients with chronic HCV infection?
- Outcomes of donor evaluation in adult-to-adult living donor liver transplantation.
- Treatment of chronic HCV in advanced liver Disease: unmet challenges, reason for optimism.
- Pharmacokinetics of enteric-coated mycophenolate sodium in stable liver transplant recipients.
- Sirolimus and liver transplantation: clinical implications for hepatocellular carcinoma.
- Severe psychiatric problems in right hepatic lobe donors for living donor liver transplantation.
- Predictors of long-term outcome following liver transplantation for hepatocellular carcinoma: a single-center experience.
- Living donor liver transplantation: is the hype over?
- Immunosuppression: evolution in practice and trends, 1993-2003.
- Hepatic artery chemoembolization for hepatocellular carcinoma in patients listed for liver transplantation.
- Role of adult living donor liver transplantation in patients with Hepatitis C.
- Treatment of advanced Hepatitis C with a low accelerating dosage regimen of antiviral therapy.
- The role of TIPS for portal vein patency in liver transplant patients with portal vein thrombosis.
- Adult right lobe live donor liver transplantation without reconstruction of the middle hepatic vein: a single-center study of 109 cases.
- Malpositioned transjugular intrahepatic portoSystemic shunt in the common hepatic duct leading to biliary obstruction and liver transplantation.
- Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma.
- The appropriate allocation of "orphan graft" in living donor liver transplantation: Simple solutions to a complex problem.
- Risk factors and impact of chronic obstructive pulmonary Disease in candidates for liver transplantation.
Procedures Preformed
- Colonoscopy, Proctosigmoidoscopy, and Sigmoidoscopy
- Endoscopy (Esophagus, Stomach, Small Intestine)
- Liver Biopsy
Conditions Treated
- Abdominal Pain
- Anemia
- Barrett's Esophagus
- Benign Neoplasm of the Digestive System
- View All
Doctors Specialties
- Gastroenterology
- Transplant Hepatology
Accepted Insurances
Awards
- Regional Top Doctor
Education
-
Duke University Hospital -
Emory University School of Medicine
Hospital
-
Baylor University Medical Center -
Baylor All Saints Medical Center at Fort Worth
Drug Facts
| NPI NUMBER | 1225128903 | |
| NPPES Provider LastName | TROTTER | |
| NPPES Provider FirstName | JAMES | |
| NPPES Provider ZIPCode | 752462003 | |
| NPPES Provider State | TX | |
| Specialty Description | Gastroenterology | |
| Total Claim Count | 594.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 57.0 | |
| Percent Opioid Claims | 9.6 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1225128903 |
| Last Name Of The Provider | TROTTER |
| First Name Of The Provider | JAMES |
| View All |
Similar Doctors
|
|
Dr. John W. Secor, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James S. Burdick, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gary L. Davis, MD |
|
|
Dr. Maria R. Lepe-Suastegui, MD |
|
|
Dr. John G. Fitz, MD |
|
|
Dr. Linda A. Feagins, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lyman E. Bilhartz, MD |
|
|
Dr. Stuart J. Spechler, MD
This Doctor is OpenDoctor Recommended.
|